Effects of thymosin beta 4 and thymosin beta 10 on actin structures in living cells.

Yu FX, Lin SC, Morrison-Bogorad M, Yin HL

Cell motility and the cytoskeleton1 Jan 1994Cited by 86 (Europe PMC)

PMID8194107DOI10.1002/cm.970270103PepBankPUB-08194107

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01LabEndogenous levelEx vivo tissueMechanism
In peritoneal macrophages, immunofluorescence showed that thymosin beta‑4 and thymosin beta 10 were uniformly distributed within the cytoplasm.
In plain wordsIn cells, the body's own thymosin beta‑4 and beta 10 were spread evenly through the cytoplasm of macrophages.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableIntracellular distribution of beta-thymosins
Study
n: not reported in source
Peritoneal macrophages
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
Immunofluorescence labeling of peritoneal macrophages showed that both beta-thymosins are uniformly distributed within the cytoplasm
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0819410701

Studies that did not test the peptide alone7

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In CV1 fibroblasts, overexpression of thymosin beta‑4 and thymosin beta 10 caused extensive loss of phalloidin-stained actin stress fibers.
In plain wordsIn cells, overexpressing thymosin beta‑4 and beta 10 caused extensive loss of actin stress fibers.
Peptide
Thymosin beta-4 (human)
Outcome
DecreasePhalloidin-stained actin stress fibers
Study
n: not reported in source
CV1 fibroblasts
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
cDNA-mediated overexpression of beta-thymosins in CV1 fibroblasts induced extensive loss of phalloidin-stained actin stress fibers.
1 context sentence(design, population, supporting numbers)
Summary · context
To study the cellular function of beta-thymosins, we have used isoform-specific antibodies to determine their concentration and intracellular distribution, and examined the effects of inducing overexpression of T beta 4 and T beta 10 on actin filament structures.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-0819410702
03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In CV1 fibroblasts overexpressing beta-thymosins, stress fibers in the cell center were more susceptible to loss than those at the periphery.
In plain wordsIn cells overexpressing thymosin beta‑4 and beta 10, stress fibers in the cell center were lost more easily than those at the edge.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableSusceptibility of central versus peripheral stress fibers
Study
n: not reported in source
CV1 fibroblasts
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
Stress fibers in the cell center were more susceptible than those at the periphery.
1 context sentence(design, population, supporting numbers)
Summary · context
To study the cellular function of beta-thymosins, we have used isoform-specific antibodies to determine their concentration and intracellular distribution, and examined the effects of inducing overexpression of T beta 4 and T beta 10 on actin filament structures.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-0819410703
04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In CV1 fibroblasts overexpressing beta-thymosins, the number of focal adhesions decreased, shown by less discrete vinculin staining.
In plain wordsIn cells overexpressing thymosin beta‑4 and beta 10, there were fewer focal adhesions.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseNumber of focal adhesions
Study
n: not reported in source
CV1 fibroblasts
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
There was a decrease in the number of focal adhesions, as evidenced by a decrease in discrete vinculin staining
1 context sentence(design, population, supporting numbers)
Summary · context
To study the cellular function of beta-thymosins, we have used isoform-specific antibodies to determine their concentration and intracellular distribution, and examined the effects of inducing overexpression of T beta 4 and T beta 10 on actin filament structures.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-0819410704
05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In CV1 fibroblasts overexpressing beta-thymosins, diffuse vinculin fluorescence increased.
In plain wordsIn cells overexpressing thymosin beta‑4 and beta 10, vinculin fluorescence became more diffuse.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseDiffuse vinculin fluorescence
Study
n: not reported in source
CV1 fibroblasts
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
an increase in diffuse vinculin fluorescence.
1 context sentence(design, population, supporting numbers)
Summary · context
To study the cellular function of beta-thymosins, we have used isoform-specific antibodies to determine their concentration and intracellular distribution, and examined the effects of inducing overexpression of T beta 4 and T beta 10 on actin filament structures.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-0819410705
06LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In CV1 fibroblasts overexpressing beta-thymosins, most transfected cells kept a normal shape despite extensive loss of actin filaments.
In plain wordsIn cells overexpressing thymosin beta‑4 and beta 10, most cells kept a normal shape even with much less actin filament.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeCell shape
Study
n: not reported in source
CV1 fibroblasts
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
The majority of the transfected cells had normal shape in spite of extensive loss of actin filaments.
1 context sentence(design, population, supporting numbers)
Summary · context
To study the cellular function of beta-thymosins, we have used isoform-specific antibodies to determine their concentration and intracellular distribution, and examined the effects of inducing overexpression of T beta 4 and T beta 10 on actin filament structures.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-0819410706
07LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
Occasional CV1 fibroblasts overexpressing beta-thymosin were observed to divide.
In plain wordsIn cells overexpressing thymosin beta‑4 and beta 10, some cells were still seen to divide.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableCell division in beta-thymosin overexpressing cells
Study
n: not reported in source
CV1 fibroblasts
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
Occasionally, cells overexpressing beta-thymosin were observed to divide.
1 context sentence(design, population, supporting numbers)
Summary · context
To study the cellular function of beta-thymosins, we have used isoform-specific antibodies to determine their concentration and intracellular distribution, and examined the effects of inducing overexpression of T beta 4 and T beta 10 on actin filament structures.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-0819410707
08LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In dividing CV1 fibroblasts overexpressing beta-thymosin, beta-thymosin was excluded from the midbody, which contains an actin filament-rich contractile ring.
In plain wordsIn dividing cells overexpressing thymosin beta‑4 and beta 10, the peptide stayed out of the midbody, which is rich in actin filaments.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableBeta-thymosin location in dividing cells
Study
n: not reported in source
CV1 fibroblasts
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
In these cells, beta-thymosin was excluded from the midbody which contains an actin filament-rich contractile ring.
1 context sentence(design, population, supporting numbers)
Summary · context
To study the cellular function of beta-thymosins, we have used isoform-specific antibodies to determine their concentration and intracellular distribution, and examined the effects of inducing overexpression of T beta 4 and T beta 10 on actin filament structures.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-0819410708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.